BLACK DIAMOND THERAPEUTICS, INC. Earnings Per Share (Basic)
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Earnings Per Share (Basic) of -$0.17 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.17.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.16, a 116.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $391.24.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.15.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was $0.39.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$1.27.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$1.88.
- BLACK DIAMOND THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$2.52.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.17 10-Q · filed 2026-08-05 | -$0.33 10-Q · filed 2026-08-05 | $389.88 derived: net income ÷ weighted average shares · filed 2026-08-05 | $390.23 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.16 10-Q · filed 2026-05-07 | $390.54 derived: net income ÷ weighted average shares · filed 2026-08-05 | $390.90 derived: net income ÷ weighted average shares · filed 2026-08-05 | $391.19 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | $391.24 derived: net income ÷ weighted average shares · filed 2026-04-29 | $391.59 derived: net income ÷ weighted average shares · filed 2026-04-29 | $391.86 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.39 10-K · filed 2026-03-16 |
| 2025-09-30 | -$0.15 10-Q · filed 2025-11-06 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.66 10-Q · filed 2025-11-06 | -$1226.08 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.19 10-Q · filed 2026-08-05 | $0.81 10-Q · filed 2026-08-05 | -$1227.19 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1228.48 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | $1.00 10-Q · filed 2026-05-07 | -$1228.17 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1229.42 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1237.65 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | -$1229.66 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1231.14 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1241.80 derived: net income ÷ weighted average shares · filed 2026-04-29 | -$1.27 10-K · filed 2026-03-16 |
| 2024-09-30 | -$0.28 10-Q · filed 2025-11-06 | -$0.64 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.99 10-Q · filed 2025-11-06 | -$1.36 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$0.36 10-Q · filed 2025-08-07 | -$0.71 10-Q · filed 2025-08-07 | -$1.09 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.54 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-03-31 | -$0.35 10-Q · filed 2025-05-12 | -$0.73 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.18 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.67 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2023-12-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2025-03-06 | -$0.83 derived: net income ÷ weighted average shares · filed 2025-03-06 | -$1.33 derived: net income ÷ weighted average shares · filed 2025-03-06 | -$1.88 10-K · filed 2025-03-06 |
| 2023-09-30 | -$0.45 10-Q · filed 2024-11-05 | -$0.96 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.54 10-Q · filed 2024-11-05 | -$2.10 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-06-30 | -$0.52 10-Q · filed 2024-08-06 | -$1.09 10-Q · filed 2024-08-06 | -$1.68 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.27 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-03-31 | -$0.57 10-Q · filed 2024-05-09 | -$1.15 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.75 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.38 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2022-12-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2024-03-12 | -$1.17 derived: net income ÷ weighted average shares · filed 2024-03-12 | -$1.81 derived: net income ÷ weighted average shares · filed 2024-03-12 | -$2.52 10-K · filed 2024-03-12 |
| 2022-09-30 | -$0.60 10-Q · filed 2023-11-06 | -$1.23 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$1.93 10-Q · filed 2023-11-06 | -$2.64 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2022-06-30 | -$0.63 10-Q · filed 2023-08-11 | -$1.33 10-Q · filed 2023-08-11 | -$2.05 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$3.02 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2022-03-31 | -$0.70 10-Q · filed 2023-05-09 | -$1.42 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$2.39 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$3.33 derived: net income ÷ weighted average shares · filed 2023-11-06 |
| 2021-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$1.68 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$2.63 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$3.47 10-K · filed 2023-03-09 |
| 2021-09-30 | -$0.97 10-Q · filed 2022-11-08 | -$1.92 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$2.76 10-Q · filed 2022-11-08 | -$3.39 derived: net income ÷ weighted average shares · filed 2022-11-08 |
| 2021-06-30 | -$0.95 10-Q · filed 2022-08-09 | -$1.79 10-Q · filed 2022-08-09 | -$2.42 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$2.92 derived: net income ÷ weighted average shares · filed 2022-11-08 |
| 2021-03-31 | -$0.84 10-Q · filed 2022-05-11 | -$1.47 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.97 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$2.37 derived: net income ÷ weighted average shares · filed 2022-11-08 |
| 2020-12-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$1.13 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$1.53 derived: net income ÷ weighted average shares · filed 2022-03-17 | -$2.05 10-K · filed 2022-03-17 |
| 2020-09-30 | -$0.50 10-Q · filed 2021-11-08 | -$0.90 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.42 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$0.41 10-Q · filed 2021-08-12 | -$0.92 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$0.51 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |